1-甲基-4-(4-甲基苯基)-3,6-二氢-2H-吡啶 | 69675-08-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-甲基-4-(4-甲基苯基)-3,6-二氢-2H-吡啶
• 英文名称: 1-methyl-4-(4-methylphenyl)-1,2,3,6-tetrahydropyridine
• 英文别名: Pyridine, 1,2,3,6-tetrahydro-1-methyl-4-(4-methylphenyl)-；1-methyl-4-(4-methylphenyl)-3,6-dihydro-2H-pyridine
• CAS: 69675-08-7
• 化学式: C₁₃H₁₇N
• 分子量: 187.285
• InChiKey: FYGYUAWBZTYALW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-甲基-4-(4-甲基苯基)-3,6-二氢-2H-吡啶 在 potassium permanganate 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以63%的产率得到N-methyl-N-(3-oxo-3-p-tolylpropyl)formamide
  参考文献：
  名称：

  摘要：

  DOI：

  10.1023/a:1012495323470
• 作为产物：
  描述：

  N-甲基-4-哌啶酮 在 盐酸 、 溶剂黄146 作用下， 以 乙醚 为溶剂， 反应 11.0h， 生成 1-甲基-4-(4-甲基苯基)-3,6-二氢-2H-吡啶
  参考文献：
  名称：

  In vivo intracerebral microdialysis studies in rats of MPP+ (1-methyl-4-phenylpyridinium) analogs and related charged species

  摘要：

  The in vivo dopaminergic neurotoxic properties of 45 MPTP and MPP+ analogues and related compounds were examined by an intrastriatal microdialysis assay in conscious rats. MPP(+)-like toxicity, as evidenced by the irreversible effects on DA release and enhancement of lactate formation, was observed with a variety of structural types although no compound was more toxic than MPP+. The following global structure-toxicity relationships could be derived: (1) only permanently charged compounds showed neurotoxic effects; (2) with the exception of amino groups, hydrophilic substituents abolished toxicity; (3) activity was enhanced by lipophilic groups although increased steric bulk around the nitrogen atom tended to decrease activity; (4) nonaromatic, quaternary systems (methiodide of MPTP, guanidinium derivatives) were only weakly toxic; and (5) certain bi- and tricyclic systems, including putative metabolites of potential endogenous MPTP-like compounds, were weakly toxic. The lack of toxic effects following perfusions with DA itself confirmed that MPTP dopaminergic neurotoxicity is not likely to be mediated by the MPP(+)-induced release of DA. With some interesting exceptions, these in vivo data correlate reasonably well with in vitro data on the nerve terminal uptake properties and the inhibitory effects on mitochondrial respiration of these compounds.

  DOI：

  10.1021/jm00170a029

文献信息

• <i>para</i>-Selective arylation and alkenylation of monosubstituted arenes using thianthrene <i>S</i>-oxide as a transient mediator
  作者：Xiao-Yue Chen、Xiao-Xue Nie、Yichen Wu、Peng Wang

  DOI：10.1039/d0cc00641f

  日期：——

  Using thianthrene S-oxide (TTSO) as a transient mediator, para-arylation and alkenylation of mono-substituted arenes have been demonstrated via a para-selective thianthrenation/Pd-catalyzed thio-Suzuki-Miyaura coupling sequence under mild conditions. This reaction features a broad substrate scope, and functional group and heterocycle tolerance. The versatility of this approach was further demonstrated

  使用噻吩硫氧化物（TTSO）作为瞬时介体，单取代的芳烃的对位芳构化和烯基化反应已通过在温和条件下通过对位选择性噻吩化/ Pd催化的硫代-Suzuki-Miyaura偶联序列进行。该反应具有广泛的底物范围，官能团和杂环耐受性。复杂的生物活性支架的后期功能化以及一些药物的直接合成，进一步证明了这种方法的多功能性，包括Tetriprofen，Ibuprofen，Bifonazole和LJ570。
• 对位取代芳基化合物的制备方法
  申请人：中国科学院上海有机化学研究所

  公开号：CN111187130B

  公开（公告）日：2021-12-14

  本发明公开了一种如式(I)所示的对位取代芳基化合物的制备方法，其特征在于，包括以下步骤：惰性气氛下，溶剂中，在碱和钯催化剂的作用下，如式(II)所示的芳基锍盐与如式(III)所示的硼化物进行偶联反应，即可。该方法以单取代芳烃为底物，原位构建芳基锍盐，钯催化剂催化原位构建的芳基锍盐发生Suzuki‑Miyaura偶联反应，快速高效构建单取代芳烃对位芳基化或烯基化产物。该方法条件温和，底物普适性高，杂环偶联底物耐受性广泛。
• HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20160096834A1

  公开（公告）日：2016-04-07

  The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

  本发明涉及咪唑吡啶化合物及其药学上可接受的组合物，用作BTK抑制剂。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：PAKINAX PTY LTD

  公开号：WO2022000031A1

  公开（公告）日：2022-01-06

  Described herein are compounds that are inhibitors of p21-activated kinases (PAKS). In particular, the compounds described herein are demonstrated to be selective PAK4 inhibitors. The compounds described herein are also demonstrated to reduce the expression of key immune checkpoint molecules, such as PD-1 and CHEK2. Also described herein are pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, more specifically, the treatment of pancreatic and lung cancers, and to related uses.

  本文描述了一些抑制p21激活激酶（PAKS）的化合物。特别地，本文描述的化合物被证明是选择性PAK4抑制剂。本文描述的化合物还被证明可以减少关键的免疫检查点分子的表达，例如PD-1和CHEK2。本文还描述了含有这些化合物的药物组合物，使用这些化合物治疗癌症的方法，更具体地说，治疗胰腺和肺癌，以及相关用途。
• NOVEL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：US20150299134A1

  公开（公告）日：2015-10-22

  There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供一种化合物，其化学式为（I）或其药学上可接受的盐。还提供了制备化合物1的方法，以及将化合物1用作药物治疗癌症的用途。